Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota.
The aims of this study were (i) to evaluate the effect of recommended antimicrobial treatment of Helicobacter pylori infection, consisting of clarithromycin, amoxicillin and lansoprazole, on intestinal microbiota and (ii) to determine the ability of a probiotic combination containing Lactobacillus rhamnosus GG, L. rhamnosus LC705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve Bb99 to prevent treatment-induced alterations in the intestinal microbiota. Faecal samples were obtained from 39 H. pylori-infected patients randomised into two treatment groups. In addition, 19 H. pylori-negative volunteers were included in the study as a control group. Samples were collected before, during and after treatment and microbiota were analysed by fluorescence in situ hybridisation and culture. The quantities of the predominant bacterial groups were altered significantly in both groups and disturbances were seen even 9 weeks after treatment was complete. Probiotics slightly counteracted the effects of anti-H. pylori treatment, seen as significantly less alterations in the total numbers of aerobes and lactobacilli/enterococci. At baseline, the composition of the microbiota between H. pylori-positive versus H. pylori-negative control individuals differed with regard to clostridia and the total number of anaerobes. The recommended treatment for H. pylori infection induces long-term disturbances in the intestinal microbiota. The probiotic combination appeared to result in only minor changes in the microbiota.
Myllyluoma
E
E
Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland; Foundation for Nutrition Research, Helsinki, Finland.
Ahlroos
T
T
Veijola
L
L
Rautelin
H
H
Tynkkynen
S
S
Korpela
R
R
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001420:Bacteria, Aerobic / Q000187:drug effects / Q000302:isolation & purification; D001421:Bacteria, Anaerobic / Q000187:drug effects / Q000302:isolation & purification; D001644:Bifidobacterium / Q000502:physiology; D002452:Cell Count; D017291:Clarithromycin / Q000494:pharmacology / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005243:Feces / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy / Q000382:microbiology / Q000628:therapy*; D016480:Helicobacter pylori; D006801:Humans; D007422:Intestines / Q000187:drug effects* / Q000382:microbiology; D052201:Lacticaseibacillus rhamnosus / Q000502:physiology; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000627:therapeutic use*; D011424:Propionibacterium / Q000502:physiology; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin